Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: N05AX12

Abilify MyCite(aripiprazole)

Schizophrenia;Bipolar Disorder

Marketing Authorisation Holder: Otsuka Pharmaceutical Netherlands B.V.

INN: aripiprazole

Indication

Treatment of schizophrenia, or of moderate to severe manic episodes in bipolar I disorder with sensor to measure medication adherence

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Abilify MyCite — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.